AbbVie moved ahead with its $10.1 billion acquisition of antibody-drug conjugate biotech ImmunoGen, while Bristol Myers Squibb’s big acquisition of radiopharmaceuticals biotech RayzeBio is likely on the way too, despite the Federal Trade Commission’s heightened attention on pharma M&A.
Read the full article: FTC Review Periods End for AbbVie-Immunogen $10.1B Deal and $4B BMS-RayzeBio Buyout //
Source: https://endpts.com/ftc-review-periods-end-for-abbvie-immunogen-10-1b-deal-and-4b-bms-rayzebio-buyout